Original Publication Date: 1 August, 2014
Publication / Source: Lung Cancer Management
Authors: Katja Schmitz, Hans-Ulrich Schildhaus
Background: Lung cancer is the leading cause of cancer related death worldwide. Molecular targeted therapies are routinely used for pulmonary adenocarcinomas, harboring therapeutically tractable genomic aberrations such as EGFR mutations, ALK and ROS1 fusions. Comparable therapeutic options are still missing for squamous and small-cell lung cancer.